non-muscle invasive bladder cancer

December 9, 2019

FDA Grants N-803 Combo Breakthrough Therapy Status for Non-Muscle Invasive Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ImmunityBio‘s interleukin-15 (IL-15) agonist N-803, in combination with Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive ... Read more

November 9, 2018November 9, 2018

Keytruda Elicits Complete Response in 40% of Group of High-risk Bladder Cancer Patients, Early Phase 2 Trial Data Show

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ongoing Phase 2 trial, Merck (known as MSD outside ... Read more

May 4, 2017

FDA Fast Tracks Development of Combo Therapy for Non-muscle Invasive Bladder Cancer

News

The U.S. Food and Drug Administration has granted fast track status to Altor Bioscience‘s ALT-803 in combination with bacillus Calmette-Guérin (BCG) for the treatment of patients with non-muscle invasive bladder cancer ... Read more